<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456948</url>
  </required_header>
  <id_info>
    <org_study_id>01EE1401F</org_study_id>
    <nct_id>NCT02456948</nct_id>
  </id_info>
  <brief_title>Adjunct Minocyline in Treatment-resistant Depression</brief_title>
  <acronym>Mino-TRD</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Unipolar Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the antidepressant efficacy of minocycline as an adjunct to an
      antidepressant standard treatment with es-/citalopram, venlafaxine or mirtazapine monotherapy
      (AD-ST), for patients with unipolar major depressive disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, multicenter proof-of-principle trial
      of adjunctive minocycline for patients with unipolar major depressive disorder (MDD). The
      study tests the antidepressant efficacy of minocycline as an adjunct to an antidepressant
      standard treatment with es-/citalopram, venlafaxine or mirtazapine monotherapy (AD-ST), for
      patients with unipolar major depressive disorder (MDD). The respective AD, for which
      non-response has been documented, must be on a stable regimen for at least 14 days prior to
      inclusion. AD-ST will then be continued throughout the trial. Trial medication is adjunct
      oral minocycline 200 mg/day or placebo. Response to treatment will be measured via the
      Montgomery-Asberg Depression Rating Scale (MADRS). The total study duration for each patient
      will be 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response as per MADRS (Montgomery-Åsberg Depression Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission as per MADRS (Montgomery-Åsberg Depression Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-D-17-Scale (17-item Hamilton Depression Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDI-Scale (Beck Depression Inventory, Self Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-Scale (Clinical Global Impressions Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCL-90-R (Symptom Checklist 90-R, Self Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic changes in patient-specific peripheral blood-derived monocytic cells</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein levels of various inflammation-associated markers in patient sera</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline and standard antidepressant treatment (es-/citalopram, venlafaxine or mirtazapine monotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and standard antidepressant treatment (es-/citalopram, venlafaxine or mirtazapine monotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>6 weeks 200mg/day Minocycline add-on</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Solodyn</other_name>
    <other_name>Minocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 weeks Placebo add-on</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pills, mimics Minocycline tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  male or female

          -  between age 18 and 75

          -  BMI between 18 and 40 inclusive

          -  Non-lactating, non-pregnant females of child-bearing potential must be willing to use
             an effective contraceptive method

          -  All participants must fulfil diagnostic criteria of moderate or severe MDD according
             to the DSM-5.

          -  HAMD-17 score of at least 16 points at baseline and a

          -  CGI-S score of at least 4.

          -  AD-ST must have been administered at a sufficient dose for at least 6 weeks in the
             current episode and at a

          -  stable regimen for at least 14 days prior to baseline.

          -  Dose and duration of AD-ST must be verifiable

        Exclusion Criteria:

          -  prevalence of neurodegenerative disorder

          -  prevalence of any neurological disorder that caused the depressive symptoms

          -  prevalence of any severe, unstable general medical condition, including chronic
             inflammatory disease such as rheumatoid arthritis or inflammatory bowel disease

          -  prevalence of any other psychiatric disorder that better explains the presence of
             depressive symptoms

          -  Improvement by more than 50% in HAMD-17 score during the last 14 days prior to
             baseline

          -  pregnant or nursing women will not be allowed.

          -  substance or alcohol abuse within past 6 months or positive urine drug screening

          -  abnormal thyroid function (euthyroid at presentation), liver or kidney dysfunction

          -  history of autoimmune disease (except Hashimotos thyroiditis)

          -  clinically significant laboratory abnormalities (outside normal ranges)

          -  current medication with anti-inflammatory substances (NSAIDs, corticosteroids)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabella Heuser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chair: Department of Psychiatry Charité - Campus Benjamn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julian Hellmann-Regen, MD</last_name>
    <email>Julian.Hellmann@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vera Clemens, MD</last_name>
    <email>Vera.Clemens@charite.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heidelberg University Hospital, Department of Psychiatry</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egle Simulionyte, MD</last_name>
      <phone>+49-(0)6221-56-5472</phone>
    </contact>
    <investigator>
      <last_name>Oliver Gruber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Roesch-Ely, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Universitiy Hospital</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Kornhuber, MD</last_name>
      <phone>+49 (0)9131 85-33001</phone>
    </contact>
    <investigator>
      <last_name>Johannes Kornhuber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Manuel Maler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, LMU Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Görlitz</last_name>
      <phone>+49 (0)89-4400-55861</phone>
      <email>thomas.goerlitz@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Cornelius Schüle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Padberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Max Planck Institute of Psychiatry</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Ising, PG</last_name>
      <phone>+49 (0)89 306221</phone>
      <email>ising@psych.mpg.de</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Martin Keck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanne Lucae, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Universitiy Hospital</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Baghai, MD</last_name>
      <phone>+449 (0)941 941-1004</phone>
    </contact>
    <investigator>
      <last_name>Thomas Baghai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Wetter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Goya-Maldonado, MD</last_name>
      <phone>+49 (0) 551 39-22244</phone>
      <email>roberto.goya@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Roberto Goya-Maldonado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Wiltfang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Charité - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Hellmann, MD</last_name>
      <email>Julian.Hellmann@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Vera Clemens, MD</last_name>
      <email>Vera.Clemens@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Isabella Heuser, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Isabella Heuser</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>treatment resistant depression</keyword>
  <keyword>inflammation</keyword>
  <keyword>microglia</keyword>
  <keyword>minocycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

